Related Experiment Video
Updated: Jun 8, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Case report: Long-term outcome post-heart transplantation in a woman with Fabry's disease
Flavia Verocai1, Joe Thomas Clarke, Robert M Iwanochko
1University of Toronto, Toronto, Ontario, Canada. Flavia.Verocai@uhn.on.ca
Insights
Heart transplantation is a viable option for patients with Fabry disease cardiomyopathy. Long-term follow-up shows no disease recurrence after 14 years, supporting this treatment recommendation.
Area of Science:
- Cardiology
- Genetics
- Transplantation
Background:
- Fabry disease is an X-linked disorder causing alpha-galactosidase A deficiency and globotriaosylceramide accumulation.
- This can lead to a rare cardiomyopathy, potentially progressing to end-stage heart failure requiring heart transplantation.
- Previous concerns existed regarding disease recurrence post-transplant, similar to kidney transplant recipients.
Abstract:
Fabry's disease is an X-linked recessive disorder that results from the deficiency of alpha-galactosidase A and causes the accumulation of globotriaosylceramide (Gb3) in different tissues. It leads to a rare form of cardiomyopathy which may be complicated by end-stage heart failure and need to heart transplant. Our group described the first case of heart transplant in a woman with cardiomyopathy secondary to Fabry's disease about 12 years ago. There was uncertainty in regards to the possibility of recurrence of the disease as previously documented in kidney transplant recipients and long-term outcomes. In this report, 14 years after transplant, this woman is still alive and there is no evidence of Fabry's disease in any of the endomyocardial biopsies. Heart transplantation can be recommended for Fabry's patients with end-stage cardiomyopathy.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy